Rh disease prevention: the European Perspective-Reference-Cited by-同舟云学术

Rh disease prevention: the European Perspective

Published:2021-01-10 Issue:1 Volume:16 Page:106-118
ISSN:1751-2816
Container-title:ISBT Science Series
language:en
Short-container-title:VOXS

Author:

Toly‐Ndour Cécile¹^ORCID,Huguet‐Jacquot Stéphanie¹,Mailloux Agnès¹,Delaby Hélène¹,Canellini Giorgia²,Olsson Martin L.³⁴^ORCID,Wikman Agneta⁵^ORCID,Koelewijn Joke M.⁶,Minon Jean‐Marc⁷,Legler Tobias J.⁸,Clausen Frederik B.⁹^ORCID,Lambert Mark¹⁰,Ryan Helen¹⁰,Bricl Irena¹¹,Hasslund Sys¹²,Orzinska Agnieszka¹³,Guz Katarzyna¹³,Uhrynowska Malgorzata¹³,Matteocci Antonella¹⁴,Nogues Nuria¹⁵,Muniz‐Diaz Eduardo¹⁵,Sainio Susanna¹⁶,De Haas Masja¹⁷,Van der Schoot C. Ellen¹⁷

Affiliation:

1. Laboratory of the French National Reference Center in Perinatal Hemobiology Assistance Publique des Hôpitaux de Paris (AP‐HP) Paris France

2. Transfusion Medicine Unit Centre Hospitalier Universitaire Vaudois Lausanne Switzerland

3. Department of Laboratory Medicine Lund University Lund Sweden

4. Department of Clinical Immunology and Transfusion Medicine Office of Medical ServicesLund Sweden

5. Department of Clinical Immunology and Transfusion Medicine Intervention and Technology Karolinska Institutet Karolinska University Hospital and Clinical Science Stockholm Sweden

6. Department of Experimental Immunohaematology Sanquin Research and Landsteiner Laboratory Amsterdam The Netherlands

7. Laboratory Medicine Department of Thrombosis‐ Haemostasis and Transfusion Centre Hospitalier Régional de la Citadelle Liège Belgium

8. Department of Transfusion Medicine University Medical Center Göttingen Germany

9. Laboratory of Blood Genetics Department of Clinical Immunology Copenhagen University Hospital Copenhagen Denmark

10. Irish Blood Transfusion Service Blood Group Genetics National Blood Center Dublin Ireland

11. Department of Immunohematology Blood Transfusion Center of Slovenia Ljubljana Slovenia

12. Department of Clinical Immunology Aarhus University Hospital Aarhus Denmark

13. Department of Immunohaematology and Immunology of Blood Transfusion Institute of Haematology and Blood Transfusion Warsaw Poland

14. Department of Transfusion Medicine San Camillo Forlanini Hospital Roma Italy

15. Immunohematology Department Banc de Sang i Teixits Barcelona Spain

16. Finnish Red Cross Blood Service Helsinki Finland

17. Department of Immunohaematology Diagnostics and of Experimental Immunohaematology Sanquin Diagnostic Services and Sanquin Research Amsterdam Netherlands

Publisher

Wiley

Subject

Computer Networks and Communications,Hardware and Architecture,Software

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/voxs.12617

Reference30 articles.

1. Pathogenesis of Erythroblastosis Fetalis: Statistical Evidence

2. Anti‐D administration after childbirth for preventing Rhesus alloimmunisation;Crowther CA;Cochrane Database Syst Rev,1997

3. Routine Antenatal Anti-D Prophylaxis in Women Who Are Rh(D) Negative: Meta-Analyses Adjusted for Differences in Study Design and Quality

4. One single dose of 200 μg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy

5. Variants of RhD - current testing and clinical consequences

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maternal red blood cell alloimmunization prevalence in the United States;Blood Advances;2024-08-15

2. Evaluation of the LightCycler® PRO Instrument as a Platform for Rhesus D Typing;Biomedicines;2024-08-06

3. Antenatal RHD screening to guide antenatal anti-D immunoprophylaxis in non-immunized D– pregnant women;Immunohematology;2024-04-01

4. Internationale richtlijnen voor het gebruik van Rhesus D immunoglobuline: een vergelijkend onderzoek en de plaats van foetale Rhesus D genotypering;Tijdschrift voor Geneeskunde;2023-04-13

5. Noninvasive Antenatal Screening for Fetal RhD in RhD-Negative Women to Guide Targeted Anti-D Prophylaxis;Prenatal Diagnostic Testing for Genetic Disorders;2023